The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes

Journal of Autoimmunity

Volumn 66, Issue , 2016, Pages 76-88

  Pearson, James A ^a   Wong, F Susan ^b   Wen, Li ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

B cells; Gut microbiota; Humanized mice; NOD; Type 1 diabetes

Indexed keywords

HLA ANTIGEN; INSULIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; TOLL LIKE RECEPTOR;

ANIMAL; AUTOIMMUNITY; B LYMPHOCYTE; BIOBREEDING RAT; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; INTESTINE FLORA; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; RAT; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; GASTROINTESTINAL MICROBIOME; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INSULIN; INSULIN-SECRETING CELLS; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; NOD SIGNALING ADAPTOR PROTEINS; RATS; RATS, INBRED BB; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 84953351870     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.08.019     Document Type: Review

References (204)

1. Gillespie K.M., Bain S.C., Barnett A.H., Bingley P.J., Christie M.R., Gill G.V., et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 2004, 364:1699-1700.
2. Bessaoud K., Boudraa G., Molinero de Ropolo M., de Sereday M., Marti M.L., Moser M., et al. Incidence and trends of childhood type 1 diabetes worldwide 1990-1999. Diabet. Med. 2006, 23:857-866.
3. Harjutsalo V., Sjöberg L., Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008, 371:1777-1782.
4. Evertsen J., Alemzadeh R., Wang X. Increasing incidence of pediatric type 1 diabetes mellitus in Southeastern Wisconsin: relationship with body weight at diagnosis. PloS One 2009, 4.
5. Ehehalt S., Dietz K., Willasch A.M., Neu A. Baden-Wuerttemberg diabetes I. Epidemiological perspectives on type 1 diabetes in childhood and adolescence in Germany - 20 years of the Baden-Wurttemberg diabetes incidence registry (DIARY). Diabetes Care 2010, 33:338-340.
6. Nakhooda A.F., Like A.A., Chappel C.I., Murray F.T., Marliss E.B. The spontaneously diabetic Wistar rat. Metabolic and morphologic studies. Diabetes 1977, 26:100-112.
7. Makino S., Kunimoto K., Muraoka Y., Mizushima Y., Katagiri K., Tochino Y. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 1980, 29:1-13.
8. Jackson R., Rassi N., Crump T., Haynes B., Eisenbarth G.S. The BB diabetic rat. Profound T-cell lymphocytopenia. Diabetes 1981, 30:887-889.
9. Elder M.E., Maclaren N.K. Identification of profound peripheral T lymphocyte immunodeficiencies in the spontaneously diabetic BB rat. J. Immunol. 1983, 130:1723-1731.
10. Jackson R., Kadison P., Buse J., Rassi N., Jegasothy B., Eisenbarth G.S. Lymphocyte abnormalities in the BB rat. Metabolism 1983, 32:83-86.
11. Yale J.F., Grose M., Marliss E.B. Time course of the lymphopenia in BB rats. Relation to the onset of diabetes. Diabetes 1985, 34:955-959.
12. Awata T., Guberski D.L., Like A.A. Genetics of the BB rat: association of autoimmune disorders (diabetes, insulitis, and thyroiditis) with lymphopenia and major histocompatibility complex class II. Endocrinology 1995, 136:5731-5735.
13. Jansen A., Homo-Delarche F., Hooijkaas H., Leenen P.J., Dardenne M., Drexhage H.A. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. Diabetes 1994, 43:667-675.
14. Bouma G., Coppens J.M., Mourits S., Nikolic T., Sozzani S., Drexhage H.A., et al. Evidence for an enhanced adhesion of DC to fibronectin and a role of CCL19 and CCL21 in the accumulation of DC around the pre-diabetic islets in NOD mice. Eur. J. Immunol. 2005, 35:2386-2396.
15. Diana J., Simoni Y., Furio L., Beaudoin L., Agerberth B., Barrat F., et al. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat. Med. 2013, 19:65-73.
16. Willcox A., Richardson S.J., Bone A.J., Foulis A.K., Morgan N.G. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 2009, 155:173-181.
17. Voorbij H.A., Jeucken P.H., Kabel P.J., De Haan M., Drexhage H.A. Dendritic cells and scavenger macrophages in pancreatic islets of prediabetic BB rats. Diabetes 1989, 38:1623-1629.
18. Lee K.U., Amano K., Yoon J.W. Evidence for initial involvement of macrophage in development of insulitis in NOD mice. Diabetes 1988, 37:989-991.
19. Nikolic T., Geutskens S.B., van Rooijen N., Drexhage H.A., Leenen P.J. Dendritic cells and macrophages are essential for the retention of lymphocytes in (peri)-insulitis of the nonobese diabetic mouse: a phagocyte depletion study. Lab. Investig. 2005, 85:487-501.
20. Van Belle T.L., Juntti T., Liao J., von Herrath M.G. Pre-existing autoimmunity determines type 1 diabetes outcome after Flt3-ligand treatment. J. Autoimmun. 2010, 34:445-452.
21. Serreze D.V., Gaedeke J.W., Leiter E.H. Hematopoietic stem-cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:9625-9629.
22. Serreze D.V., Gaskins H.R., Leiter E.H. Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. J. Immunol. 1993, 150:2534-2543.
23. Prasad S.J., Goodnow C.C. Intrinsic in vitro abnormalities in dendritic cell generation caused by non-MHC non-obese diabetic genes. Immunol. Cell Biol. 2002, 80:198-206.
24. Steptoe R.J., Ritchie J.M., Harrison L.C. Increased generation of dendritic cells from myeloid progenitors in autoimmune-prone nonobese diabetic mice. J. Immunol. 2002, 168:5032-5041.
25. Feili-Hariri M., Morel P.A. Phenotypic and functional characteristics of BM-derived DC from NOD and non-diabetes-prone strains. Clin. Immunol. 2001, 98:133-142.
26. Welzen-Coppens J.M., van Helden-Meeuwsen C.G., Leenen P.J., Drexhage H.A., Versnel M.A. Reduced numbers of dendritic cells with a tolerogenic phenotype in the prediabetic pancreas of NOD mice. J. Leukoc. Biol. 2012, 92:1207-1213.
27. Beumer W., Welzen-Coppens J.M., van Helden-Meeuwsen C.G., Gibney S.M., Drexhage H.A., Versnel M.A. The gene expression profile of CD11c+ CD8α- dendritic cells in the pre-diabetic pancreas of the NOD mouse. PLoS One 2014, 9:e103404.
28. Miyazaki A., Hanafusa T., Yamada K., Miyagawa J., Fujino-Kurihara H., Nakajima H., et al. Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic non-obese diabetic (NOD) mice: a longitudinal study. Clin. Exp. Immunol. 1985, 60:622-630.
29. Serreze D.V., Leiter E.H., Christianson G.J., Greiner D., Roopenian D.C. Major histocompatibility complex class I-deficient NOD-B2mnull mice are diabetes and insulitis resistant. Diabetes 1994, 43:505-509.
30. Wicker L.S., Leiter E.H., Todd J.A., Renjilian R.J., Peterson E., Fischer P.A., et al. Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes 1994, 43:500-504.
31. Yagi H., Matsumoto M., Kunimoto K., Kawaguchi J., Makino S., Harada M. Analysis of the roles of CD4+ and CD8+ T cells in autoimmune diabetes of NOD mice using transfer to NOD athymic nude mice. Eur. J. Immunol. 1992, 22:2387-2393.
32. Matsumoto M., Yagi H., Kunimoto K., Kawaguchi J., Makino S., Harada M. Transfer of autoimmune diabetes from diabetic NOD mice to NOD athymic nude mice: the roles of T cell subsets in the pathogenesis. Cell Immunol. 1993, 148:189-197.
33. Christianson S.W., Shultz L.D., Leiter E.H. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 1993, 42:44-55.
34. Chatenoud L., Thervet E., Primo J., Bach J.F. Remission of established disease in diabetic NOD mice induced by anti-CD3 monoclonal antibody. C. R. Acad. Sci. III 1992, 315:225-228.
35. Penaranda C., Tang Q., Bluestone J.A. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J. Immunol. 2011, 187:2015-2022.
36. Charlton B., Mandel T.E. Recurrence of insulitis in the NOD mouse after early prolonged anti-CD4 monoclonal antibody treatment. Autoimmunity 1989, 4:1-7.
37. Hutchings P., O'Reilly L., Parish N.M., Waldmann H., Cooke A. The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to beta cells in NOD mice. Eur. J. Immunol. 1992, 22:1913-1918.
38. Nagata M., Santamaria P., Kawamura T., Utsugi T., Yoon J.W. Evidence for the role of CD8+ cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese diabetic mice. J. Immunol. 1994, 152:2042-2050.
39. Makhlouf L., Grey S.T., Dong V., Csizmadia E., Arvelo M.B., Auchincloss H., et al. Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice. Transplantation 2004, 77:990-997.
40. Yi Z., Diz R., Martin A.J., Morillon Y.M., Kline D.E., Li L., et al. Long-term remission of diabetes in NOD mice is induced by nondepleting anti-CD4 and anti-CD8 antibodies. Diabetes 2012, 61:2871-2880.
41. Wang B., Gonzalez A., Benoist C., Mathis D. The role of CD8+ T cells in the initiation of insulin-dependent diabetes mellitus. Eur. J. Immunol. 1996, 26:1762-1769.
42. Taki T., Nagata M., Ogawa W., Hatamori N., Hayakawa M., Hari J., et al. Prevention of cyclophosphamide-induced and spontaneous diabetes in NOD/Shi/Kbe mice by anti-MHC class I Kd monoclonal antibody. Diabetes 1991, 40:1203-1209.
43. Boitard C., Bendelac A., Richard M.F., Carnaud C., Bach J.F. Prevention of diabetes in nonobese diabetic mice by anti-I-A monoclonal antibodies: transfer of protection by splenic T cells. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:9719-9723.
44. Pontesilli O., Carotenuto P., Gazda L.S., Pratt P.F., Prowse S.J. Circulating lymphocyte populations and autoantibodies in non-obese diabetic (NOD) mice: a longitudinal study. Clin. Exp. Immunol. 1987, 70:84-93.
45. Michel C., Boitard C., Bach J.F. Insulin autoantibodies in non-obese diabetic (NOD) mice. Clin. Exp. Immunol. 1989, 75:457-460.
46. De Aizpurua H.J., French M.B., Chosich N., Harrison L.C. Natural history of humoral immunity to glutamic acid decarboxylase in non-obese diabetic (NOD) mice. J. Autoimmun. 1994, 7:643-653.
47. Lamont D., Mukherjee G., Kumar P.R., Samanta D., McPhee C.G., Kay T.W., et al. Compensatory mechanisms allow undersized anchor-deficient class I MHC ligands to mediate pathogenic autoreactive T cell responses. J. Immunol. 2014, 193:2135-2146.
48. Zekzer D., Wong F.S., Wen L., Altieri M., Gurlo T., von Grafenstein H., et al. Inhibition of diabetes by an insulin-reactive CD4 T-cell clone in the nonobese diabetic mouse. Diabetes 1997, 46:1124-1132.
49. Simone E., Daniel D., Schloot N., Gottlieb P., Babu S., Kawasaki E., et al. T cell receptor restriction of diabetogenic autoimmune NOD T cells. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2518-2521.
50. Abiru N., Wegmann D., Kawasaki E., Gottlieb P., Simone E., Eisenbarth G.S. Dual overlapping peptides recognized by insulin peptide B:9-23 T cell receptor AV13S3 T cell clones of the NOD mouse. J. Autoimmun. 2000, 14:231-237.
51. Wong F.S., Visintin I., Wen L., Flavell R.A., Janeway C.A. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J. Exp. Med. 1996, 183:67-76.
52. Wong F.S., Karttunen J., Dumont C., Wen L., Visintin I., Pilip I.M., et al. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat. Med. 1999, 5:1026-1031.
53. Ejrnaes M., Videbaek N., Christen U., Cooke A., Michelsen B.K., von Herrath M. Different diabetogenic potential of autoaggressive CD8+ clones associated with IFN-gamma-inducible protein 10 (CXC chemokine ligand 10) production but not cytokine expression, cytolytic activity, or homing characteristics. J. Immunol. 2005, 174:2746-2755.
54. Lieberman S.M., Evans A.M., Han B., Takaki T., Vinnitskaya Y., Caldwell J.A., et al. Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8384-8388.
55. Stadinski B.D., Delong T., Reisdorph N., Reisdorph R., Powell R.L., Armstrong M., et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat. Immunol. 2010, 11:225-231.
56. Burton A.R., Vincent E., Arnold P.Y., Lennon G.P., Smeltzer M., Li C.S., et al. On the pathogenicity of autoantigen-specific T-cell receptors. Diabetes 2008, 57:1321-1330.
57. Chao C.C., Sytwu H.K., Chen E.L., Toma J., McDevitt H.O. The role of MHC class II molecules in susceptibility to type I diabetes: identification of peptide epitopes and characterization of the T cell repertoire. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:9299-9304.
58. Videbaek N., Harach S., Phillips J., Hutchings P., Ozegbe P., Michelsen B.K., et al. An islet-homing NOD CD8+ cytotoxic T cell clone recognizes GAD65 and causes insulitis. J. Autoimmun. 2003, 20:97-109.
59. Bowie L., Tite J., Cooke A. Generation and maintenance of autoantigen-specific CD8(+) T cell clones isolated from NOD mice. J. Immunol. Methods 1999, 228:87-95.
60. Elias D., Reshef T., Birk O.S., van der Zee R., Walker M.D., Cohen I.R. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:3088-3091.
61. Birk O.S., Elias D., Weiss A.S., Rosen A., van-der Zee R., Walker M.D., et al. NOD mouse diabetes: the ubiquitous mouse hsp60 is a beta-cell target antigen of autoimmune T cells. J. Autoimmun. 1996, 9:159-166.
62. Nayak D.K., Calderon B., Vomund A.N., Unanue E.R. In NOD mice ZnT8 reactive T cells are weakly pathogenic but can participate in diabetes under inflammatory conditions. Diabetes 2014, 63:3438-3448.
63. Nerup J., Platz P., Andersen O.O., Christy M., Lyngsoe J., Poulsen J.E., et al. HL-A antigens and diabetes mellitus. Lancet 1974, 2:864-866.
64. Singal D.P., Blajchman M.A. Histocompatibility (HL-A) antigens, lymphocytotoxic antibodies and tissue antibodies in patients with diabetes mellitus. Diabetes 1973, 22:429-432.
65. Hattori M., Buse J.B., Jackson R.A., Glimcher L., Dorf M.E., Minami M., et al. The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex. Science 1986, 231:733-735.
66. Acha-Orbea H., McDevitt H.O. The first external domain of the nonobese diabetic mouse class II I-A beta chain is unique. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:2435-2439.
67. Sato A.K., Sturniolo T., Sinigaglia F., Stern L.J. Substitution of aspartic acid at beta57 with alanine alters MHC class II peptide binding activity but not protein stability: HLA-DQ (alpha1*0201, beta1*0302) and (alpha1*0201, beta1*0303). Hum. Immunol. 1999, 60:1227-1236.
68. Lund T., O'Reilly L., Hutchings P., Kanagawa O., Simpson E., Gravely R., et al. Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A beta-chain or normal I-E alpha-chain. Nature 1990, 345:727-729.
69. Nishimoto H., Kikutani H., Yamamura K., Kishimoto T. Prevention of autoimmune insulitis by expression of I-E molecules in NOD mice. Nature 1987, 328:432-434.
70. Aly T.A., Ide A., Jahromi M.M., Barker J.M., Fernando M.S., Babu S.R., et al. Extreme genetic risk for type 1A diabetes. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14074-14079.
71. Erlich H., Valdes A.M., Noble J., Carlson J.A., Varney M., Concannon P., et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 2008, 57:1084-1092.
72. Wen L., Chen N.Y., Tang J., Sherwin R., Wong F.S. The regulatory role of DR4 in a spontaneous diabetes DQ8 transgenic model. J. Clin. Investig. 2001, 107:871-880.
73. Vafiadis P., Bennett S.T., Todd J.A., Nadeau J., Grabs R., Goodyer C.G., et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat. Genet. 1997, 15:289-292.
74. Pugliese A., Zeller M., Fernandez A., Zalcberg L.J., Bartlett R.J., Ricordi C., et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat. Genet. 1997, 15:293-297.
75. Chentoufi A.A., Polychronakos C. Insulin expression levels in the thymus modulate insulin-specific autoreactive T-cell tolerance: the mechanism by which the IDDM2 locus may predispose to diabetes. Diabetes 2002, 51:1383-1390.
76. Noble J.A., Erlich H.A. Genetics of type 1 diabetes. Cold Spring Harb. Perspect. Med. 2012, 2:a007732.
77. Bergholdt R., Brorsson C., Palleja A., Berchtold L.A., Fløyel T., Bang-Berthelsen C.H., et al. Identification of novel type 1 diabetes candidate genes by integrating genome-wide association data, protein-protein interactions, and human pancreatic islet gene expression. Diabetes 2012, 61:954-962.
78. Barnett A.H., Eff C., Leslie R.D., Pyke D.A. Diabetes in identical twins. A study of 200 pairs. Diabetologia 1981, 20:87-93.
79. Redondo M.J., Yu L., Hawa M., Mackenzie T., Pyke D.A., Eisenbarth G.S., et al. Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia 2001, 44:354-362.
80. Hyttinen V., Kaprio J., Kinnunen L., Koskenvuo M., Tuomilehto J. Genetic liability of type 1 diabetes and the onset age among 22,650 young Finnish twin pairs: a nationwide follow-up study. Diabetes 2003, 52:1052-1055.
81. Variation and trends in incidence of childhood diabetes in Europe. EURODIAB ACE Study Group. Lancet 2000, 355:873-876.
82. Bodington M.J., Muzulu S.I., Burden A.C. Spatial clustering in childhood diabetes: evidence of an environmental cause. Diabet. Med. 1995, 12:865-867.
83. Hjern A., Söderström U. Parental country of birth is a major determinant of childhood type 1 diabetes in Sweden. Pediatr. Diabetes 2008, 9:35-39.
84. Group T.S. The environmental determinants of diabetes in the young (TEDDY) study. Ann. N. Y. Acad. Sci. 2008, 1150:1-13.
85. Schmid S., Koczwara K., Schwinghammer S., Lampasona V., Ziegler A.G., Bonifacio E. Delayed exposure to wheat and barley proteins reduces diabetes incidence in non-obese diabetic mice. Clin. Immunol. 2004, 111:108-118.
86. Maurano F., Mazzarella G., Luongo D., Stefanile R., D'Arienzo R., Rossi M., et al. Small intestinal enteropathy in non-obese diabetic mice fed a diet containing wheat. Diabetologia 2005, 48:931-937.
87. Marietta E.V., Gomez A.M., Yeoman C., Tilahun A.Y., Clark C.R., Luckey D.H., et al. Low incidence of spontaneous type 1 diabetes in non-obese diabetic mice raised on gluten-free diets is associated with changes in the intestinal microbiome. PLoS One 2013, 8:e78687.
88. Cooke A., Tonks P., Jones F.M., O'Shea H., Hutchings P., Fulford A.J., et al. Infection with Schistosoma mansoni prevents insulin dependent diabetes mellitus in non-obese diabetic mice. Parasite Immunol. 1999, 21:169-176.
89. Zaccone P., Raine T., Sidobre S., Kronenberg M., Mastroeni P., Cooke A. Salmonella typhimurium infection halts development of type 1 diabetes in NOD mice. Eur. J. Immunol. 2004, 34:3246-3256.
90. Drescher K.M., Kono K., Bopegamage S., Carson S.D., Tracy S. Coxsackievirus B3 infection and type 1 diabetes development in NOD mice: insulitis determines susceptibility of pancreatic islets to virus infection. Virology 2004, 329:381-394.
91. Wen L., Ley R.E., Volchkov P.Y., Stranges P.B., Avanesyan L., Stonebraker A.C., et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 2008, 455:1109-1113.
92. Hansen C.H., Krych L., Nielsen D.S., Vogensen F.K., Hansen L.H., Sørensen S.J., et al. Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse. Diabetologia 2012, 55:2285-2294.
93. Mor F., Cohen I.R. Beta-lactam antibiotics modulate T-cell functions and gene expression via covalent binding to cellular albumin. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:2981-2986.
94. Peng J., Narasimhan S., Marchesi J.R., Benson A., Wong F.S., Wen L. Long term effect of gut microbiota transfer on diabetes development. J. Autoimmun. 2014, 53:85-94.
95. Tormo-Badia N., Håkansson A., Vasudevan K., Molin G., Ahrné S., Cilio C.M. Antibiotic treatment of pregnant non-obese diabetic (NOD) mice leads to altered gut microbiota and intestinal immunological changes in the offspring. Scand. J. Immunol. 2014, 80:250-260.
96. Kim H.S., Han M.S., Chung K.W., Kim S., Kim E., Kim M.J., et al. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 2007, 27:321-333.
97. Wong F.S., Hu C., Zhang L., Du W., Alexopoulou L., Flavell R.A., et al. The role of toll-like receptors 3 and 9 in the development of autoimmune diabetes in NOD mice. Ann. N. Y. Acad. Sci. 2008, 1150:146-148.
98. Calcinaro F., Dionisi S., Marinaro M., Candeloro P., Bonato V., Marzotti S., et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 2005, 48:1565-1575.
99. Durant S., Alves V., Coulaud J., Homo-Delarche F. Nonobese diabetic (NOD) mouse dendritic cells stimulate insulin secretion by prediabetic islets. Autoimmunity 2002, 35:449-455.
100. Saxena V., Ondr J.K., Magnusen A.F., Munn D.H., Katz J.D. The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. J. Immunol. 2007, 179:5041-5053.
101. Gaudreau S., Guindi C., Ménard M., Besin G., Dupuis G., Amrani A. Granulocyte-macrophage colony-stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4+CD25+ regulatory T cells. J. Immunol. 2007, 179:3638-3647.
102. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
103. Krutzik S.R., Tan B., Li H., Ochoa M.T., Liu P.T., Sharfstein S.E., et al. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat. Med. 2005, 11:653-660.
104. Hua Z., Hou B. TLR signaling in B-cell development and activation. Cell. Mol. Immunol. 2013, 10:103-106.
105. Rahman A.H., Taylor D.K., Turka L.A. The contribution of direct TLR signaling to T cell responses. Immunol. Res. 2009, 45:25-36.
106. Ganz T. The role of antimicrobial peptides in innate immunity. Integr. Comp. Biol. 2003, 43:300-304.
107. Fukata M., Chen A., Klepper A., Krishnareddy S., Vamadevan A.S., Thomas L.S., et al. Cox-2 is regulated by toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 2006, 131:862-877.
108. Cario E., Gerken G., Podolsky D.K. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology 2004, 127:224-238.
109. Shang L., Fukata M., Thirunarayanan N., Martin A.P., Arnaboldi P., Maussang D., et al. Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria. Gastroenterology 2008, 135:529-538.
110. Takeuchi O., Hoshino K., Akira S. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J. Immunol. 2000, 165:5392-5396.
111. Gonnella P.A., Waldner H., Del Nido P.J., McGowan F.X. Inhibition of experimental autoimmune myocarditis: peripheral deletion of TcR Vbeta 8.1, 8.2+ CD4+ T cells in TLR-4 deficient mice. J. Autoimmun. 2008, 31:180-187.
112. Gülden E., Ihira M., Ohashi A., Reinbeck A.L., Freudenberg M.A., Kolb H., et al. Toll-like receptor 4 deficiency accelerates the development of insulin-deficient diabetes in non-obese diabetic mice. PLoS One 2013, 8:e75385.
113. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25:417-428.
114. Zhang Y., Lee A.S., Shameli A., Geng X., Finegood D., Santamaria P., et al. TLR9 blockade inhibits activation of diabetogenic CD8+ T cells and delays autoimmune diabetes. J. Immunol. 2010, 184:5645-5653.
115. Tai N., Wong F.S., Wen L. TLR9 deficiency promotes CD73 expression in T cells and diabetes protection in nonobese diabetic mice. J. Immunol. 2013, 191:2926-2937.
116. Kim D.H., Lee J.C., Lee M.K., Kim K.W., Lee M.S. Treatment of autoimmune diabetes in NOD mice by toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition. Diabetologia 2012, 55:3308-3317.
117. Caricilli A.M., Picardi P.K., de Abreu L.L., Ueno M., Prada P.O., Ropelle E.R., et al. Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. PLoS Biol. 2011, 9:e1001212.
118. Richer M.J., Lavallée D.J., Shanina I., Horwitz M.S. Toll-like receptor 3 signaling on macrophages is required for survival following coxsackievirus B4 infection. PLoS One 2009, 4:e4127.
119. McCall K.D., Thuma J.R., Courreges M.C., Benencia F., James C.B., Malgor R., et al. Toll-like receptor 3 is critical for coxsackievirus B4-induced type 1 diabetes in female NOD mice. Endocrinology 2015, 156:453-461.
120. Lang K.S., Recher M., Junt T., Navarini A.A., Harris N.L., Freigang S., et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 2005, 11:138-145.
121. Zipris D., Lien E., Xie J.X., Greiner D.L., Mordes J.P., Rossini A.A. TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats. J. Immunol. 2005, 174:131-142.
122. Alkanani A.K., Hara N., Lien E., Ir D., Kotter C.V., Robertson C.E., et al. Induction of diabetes in the RIP-B7.1 mouse model is critically dependent on TLR3 and MyD88 pathways and is associated with alterations in the intestinal microbiome. Diabetes 2014, 63:619-631.
123. Tan Q., Majewska-Szczepanik M., Zhang X., Szczepanik M., Zhou Z., Wong F.S., et al. IRAK-M deficiency promotes the development of type 1 diabetes in NOD mice. Diabetes 2014, 63:2761-2775.
124. Franchi L., Park J.H., Shaw M.H., Marina-Garcia N., Chen G., Kim Y.G., et al. Intracellular NOD-like receptors in innate immunity, infection and disease. Cell Microbiol. 2008, 10:1-8.
125. Franchi L., Warner N., Viani K., Nuñez G. Function of nod-like receptors in microbial recognition and host defense. Immunol. Rev. 2009, 227:106-128.
126. Voss E., Wehkamp J., Wehkamp K., Stange E.F., Schröder J.M., Harder J. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J. Biol. Chem. 2006, 281:2005-2011.
127. Uehara A., Fujimoto Y., Fukase K., Takada H. Various human epithelial cells express functional toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol. Immunol. 2007, 44:3100-3111.
128. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
129. Hu C., Ding H., Li Y., Pearson J.A., Zhang X., Flavell R.A., et al. NLRP3 deficiency protects from type 1 diabetes through the regulation of chemotaxis into the pancreatic islets. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:11318-11323.
130. Vaarala O., Atkinson M.A., Neu J. The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 2008, 57:2555-2562.
131. Jaakkola I., Jalkanen S., Hänninen A. Diabetogenic T cells are primed both in pancreatic and gut-associated lymph nodes in NOD mice. Eur. J. Immunol. 2003, 33:3255-3264.
132. Matsuzaki T., Nagata Y., Kado S., Uchida K., Kato I., Hashimoto S., et al. Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei. APMIS 1997, 105:643-649.
133. Takiishi T., Korf H., Van Belle T.L., Robert S., Grieco F.A., Caluwaerts S., et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J. Clin. Investig. 2012, 122:1717-1725.
134. Robert S., Gysemans C., Takiishi T., Korf H., Spagnuolo I., Sebastiani G., et al. Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes 2014, 63:2876-2887.
135. Mazmanian S.K., Round J.L., Kasper D.L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008, 453:620-625.
136. Ochoa-Repáraz J., Mielcarz D.W., Ditrio L.E., Burroughs A.R., Begum-Haque S., Dasgupta S., et al. Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide A expression. J. Immunol. 2010, 185:4101-4108.
137. Ochoa-Repáraz J., Mielcarz D.W., Wang Y., Begum-Haque S., Dasgupta S., Kasper D.L., et al. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol. 2010, 3:487-495.
138. Horai R., Zarante-BlaDes C.R., Dillenburg-Pilla P., Silver P.B., Chen J., Jittayasothorn Y., et al. Microbiota-dependent activation of an autoreactive T cell receptor provokes autoimmunity in an immunological privileged site. Immunity 2015, 43:343-353.
139. Serreze D.V., Chapman H.D., Varnum D.S., Hanson M.S., Reifsnyder P.C., Richard S.D., et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J. Exp. Med. 1996, 184:2049-2053.
140. Wong F.S., Visintin I., Wen L., Granata J., Flavell R., Janeway C.A. The role of lymphocyte subsets in accelerated diabetes in nonobese diabetic-rat insulin promoter-B7-1 (NOD-RIP-B7-1) mice. J. Exp. Med. 1998, 187:1985-1993.
141. Yang M., Charlton B., Gautam A.M. Development of insulitis and diabetes in B cell-deficient NOD mice. J. Autoimmun. 1997, 10:257-260.
142. Serreze D.V., Fleming S.A., Chapman H.D., Richard S.D., Leiter E.H., Tisch R.M. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J. Immunol. 1998, 161:3912-3918.
143. Puertas M.C., Carrillo J., Pastor X., Ampudia R.M., Alba A., Planas R., et al. Phenotype and functional characteristics of islet-infiltrating B-cells suggest the existence of immune regulatory mechanisms in islet milieu. Diabetes 2007, 56:940-949.
144. Kendall P.L., Woodward E.J., Hulbert C., Thomas J.W. Peritoneal B cells govern the outcome of diabetes in non-obese diabetic mice. Eur. J. Immunol. 2004, 34:2387-2395.
145. Noorchashm H., Lieu Y.K., Noorchashm N., Rostami S.Y., Greeley S.A., Schlachterman A., et al. I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. J. Immunol. 1999, 163:743-750.
146. Ziegler A.G., Vardi P., Ricker A.T., Hattori M., Soeldner J.S., Eisenbarth G.S. Radioassay determination of insulin autoantibodies in NOD mice. Correlation with increased risk of progression to overt diabetes. Diabetes 1989, 38:358-363.
147. Robles D.T., Eisenbarth G.S., Dailey N.J., Peterson L.B., Wicker L.S. Insulin autoantibodies are associated with islet inflammation but not always related to diabetes progression in NOD congenic mice. Diabetes 2003, 52:882-886.
148. Ziegler A.G., Rewers M., Simell O., Simell T., Lempainen J., Steck A., et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013, 309:2473-2479.
149. Humphreys-Beher M.G., Brinkley L., Purushotham K.R., Wang P.L., Nakagawa Y., Dusek D., et al. Characterization of antinuclear autoantibodies present in the serum from nonobese diabetic (NOD) mice. Clin. Immunol. Immunopathol. 1993, 68:350-356.
150. Acevedo-Suárez C.A., Hulbert C., Woodward E.J., Thomas J.W. Uncoupling of anergy from developmental arrest in anti-insulin B cells supports the development of autoimmune diabetes. J. Immunol. 2005, 174:827-833.
151. Henry-Bonami R.A., Williams J.M., Rachakonda A.B., Karamali M., Kendall P.L., Thomas J.W. B lymphocyte "original sin" in the bone marrow enhances islet autoreactivity in type 1 diabetes-prone nonobese diabetic mice. J. Immunol. 2013, 190:5992-6003.
152. Hulbert C., Riseili B., Rojas M., Thomas J.W. B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice. J. Immunol. 2001, 167:5535-5538.
153. Thomas J.W., Hulbert C. Somatically mutated B cell pool provides precursors for insulin antibodies. J. Immunol. 1996, 157:763-771.
154. Kendall P.L., Moore D.J., Hulbert C., Hoek K.L., Khan W.N., Thomas J.W. Reduced diabetes in btk-deficient nonobese diabetic mice and restoration of diabetes with provision of an anti-insulin IgH chain transgene. J. Immunol. 2009, 183:6403-6412.
155. Henry R.A., Kendall P.L., Thomas J.W. Autoantigen-specific B-cell depletion overcomes failed immune tolerance in type 1 diabetes. Diabetes 2012, 61:2037-2044.
156. Hu C.Y., Rodriguez-Pinto D., Du W., Ahuja A., Henegariu O., Wong F.S., et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Investig. 2007, 117:3857-3867.
157. Hu C., Ding H., Zhang X., Wong F.S., Wen L. Combination treatment with anti-CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes. Diabetes 2013, 62:2849-2858.
158. Gürcan H.M., Keskin D.B., Stern J.N., Nitzberg M.A., Shekhani H., Ahmed A.R. A review of the current use of rituximab in autoimmune diseases. Int. Immunopharmacol. 2009, 9:10-25.
159. Hu C., Du W., Zhang X., Wong F.S., Wen L. The role of Gr1+ cells after anti-CD20 treatment in type 1 diabetes in nonobese diabetic mice. J. Immunol. 2012, 188:294-301.
160. Yang H., Bi Y., Han F., Lu Y., Wang J., Zhang Z., et al. Myeloid-derived suppressor cells in immunity and autoimmunity. Expert Rev. Clin. Immunol. 2015, 11:1-9.
161. Yan H.H., Pickup M., Pang Y., Gorska A.E., Li Z., Chytil A., et al. Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res. 2010, 70:6139-6149.
162. Yi H., Guo C., Yu X., Zuo D., Wang X.Y. Mouse CD11b+Gr-1+ myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis. J. Immunol. 2012, 189:4295-4304.
163. Herold K.C., Pescovitz M.D., McGee P., Krause-Steinrauf H., Spain L.M., Bourcier K., et al. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J. Immunol. 2011, 187:1998-2005.
164. Xiang Y., Peng J., Tai N., Hu C., Zhou Z., Wong F.S., et al. The dual effects of B cell depletion on antigen-specific T cells in BDC2.5NOD mice. J. Immunol. 2012, 188:4747-4758.
165. Todd J.A., Acha-Orbea H., Bell J.I., Chao N., Fronek Z., Jacob C.O., et al. A molecular basis for MHC class II-associated autoimmunity. Science 1988, 240:1003-1009.
166. Wen L., Wong F.S., Burkly L., Altieri M., Mamalaki C., Kioussis D., et al. Induction of insulitis by glutamic acid decarboxylase peptide-specific and HLA-DQ8-restricted CD4(+) T cells from human DQ transgenic mice. J. Clin. Investig. 1998, 102:947-957.
167. Wen L., Wong F.S., Tang J., Chen N.Y., Altieri M., David C., et al. In vivo evidence for the contribution of human histocompatibility leukocyte antigen (HLA)-DQ molecules to the development of diabetes. J. Exp. Med. 2000, 191:97-104.
168. Raju R., Munn S.R., Majoribanks C., David C.S. Islet cell autoimmunity in NOD mice transgenic for HLA-DQ8 and lacking I-Ag7. Transpl. Proc. 1998, 30:561.
169. Liu J., Purdy L.E., Rabinovitch S., Jevnikar A.M., Elliott J.F. Major DQ8-restricted T-cell epitopes for human GAD65 mapped using human CD4, DQA1*0301, DQB1*0302 transgenic IA(null) NOD mice. Diabetes 1999, 48:469-477.
170. DiLorenzo T.P., Graser R.T., Ono T., Christianson G.J., Chapman H.D., Roopenian D.C., et al. Major histocompatibility complex class I-restricted T cells are required for all but the end stages of diabetes development in nonobese diabetic mice and use a prevalent T cell receptor alpha chain gene rearrangement. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:12538-12543.
171. Kudva Y.C., Deng Y.J., Govindarajan R., Abraham R.S., Marietta E.V., Notkins A.L., et al. HLA-DQ8 transgenic and NOD mice recognize different epitopes within the cytoplasmic region of the tyrosine phosphatase-like molecule, IA-2. Hum. Immunol. 2001, 62:1099-1105.
172. Suri A., Walters J.J., Gross M.L., Unanue E.R. Natural peptides selected by diabetogenic DQ8 and murine I-A(g7) molecules show common sequence specificity. J. Clin. Investig. 2005, 115:2268-2276.
173. Nejentsev S., Howson J.M., Walker N.M., Szeszko J., Field S.F., Stevens H.E., et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007, 450:887-892.
174. Takaki T., Marron M.P., Mathews C.E., Guttmann S.T., Bottino R., Trucco M., et al. HLA-A*0201-restricted T cells from humanized NOD mice recognize autoantigens of potential clinical relevance to type 1 diabetes. J. Immunol. 2006, 176:3257-3265.
175. Irwin M.J., Heath W.R., Sherman L.A. Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response. J. Exp. Med. 1989, 170:1091-1101.
176. Hassainya Y., Garcia-Pons F., Kratzer R., Lindo V., Greer F., Lemonnier F.A., et al. Identification of naturally processed HLA-A2-restricted proinsulin epitopes by reverse immunology. Diabetes 2005, 54:2053-2059.
177. Antal Z., Baker J.C., Smith C., Jarchum I., Babad J., Mukherjee G., et al. Beyond HLA-A*0201: new HLA-transgenic nonobese diabetic mouse models of type 1 diabetes identify the insulin C-peptide as a rich source of CD8+ T cell epitopes. J. Immunol. 2012, 188:5766-5775.
178. Li Y., Zhou L., Zhang J., Guo B., Meng G., Chen X., et al. Identification of autoreactive CD8(+) T cell responses targeting chromogranin A in humanized NOD mice and type 1 diabetes patients. Clin. Immunol. 2015, 159:63-71.
179. Niens M., Grier A.E., Marron M., Kay T.W., Greiner D.L., Serreze D.V. Prevention of "Humanized" diabetogenic CD8 T-cell responses in HLA-transgenic NOD mice by a multipeptide coupled-cell approach. Diabetes 2011, 60:1229-1236.
180. Pow Sang L., Majji S., Casares S., Brumeanu T.D. Long-term silencing of autoimmune diabetes and improved life expectancy by a soluble pHLA-DR4 chimera in a newly-humanized NOD/DR4/B7 mouse. Hum. Vaccin Immunother. 2014, 10:693-699.
181. Lin M., Stoica-Nazarov C., Surls J., Kehl M., Bona C., Olsen C., et al. Reversal of type 1 diabetes by a new MHC II-peptide chimera: "Single-epitope-mediated suppression" to stabilize a polyclonal autoimmune T-cell process. Eur. J. Immunol. 2010, 40:2277-2288.
182. Gale E.A., Gillespie K.M. Diabetes and gender. Diabetologia 2001, 44:3-15.
183. Roep B.O. Are insights gained from NOD mice sufficient to guide clinical translation? Another inconvenient truth. Ann. N. Y. Acad. Sci. 2007, 1103:1-10.
184. Greiner D.L., Shultz L.D., Yates J., Appel M.C., Perdrizet G., Hesselton R.M., et al. Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice. Am. J. Pathol. 1995, 146:888-902.
185. Yoshino H., Ueda T., Kawahata M., Kobayashi K., Ebihara Y., Manabe A., et al. Natural killer cell depletion by anti-asialo GM1 antiserum treatment enhances human hematopoietic stem cell engraftment in NOD/Shi-scid mice. Bone Marrow Transpl. 2000, 26:1211-1216.
186. Kollet O., Peled A., Byk T., Ben-Hur H., Greiner D., Shultz L., et al. beta2 microglobulin-deficient (B2m(null)) NOD/SCID mice are excellent recipients for studying human stem cell function. Blood 2000, 95:3102-3105.
187. van Halteren A.G., Kardol M.J., Mulder A., Roep B.O. Homing of human autoreactive T cells into pancreatic tissue of NOD-scid mice. Diabetologia 2005, 48:75-82.
188. Cao X., Shores E.W., Hu-Li J., Anver M.R., Kelsall B.L., Russell S.M., et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 1995, 2:223-238.
189. Ito M., Hiramatsu H., Kobayashi K., Suzue K., Kawahata M., Hioki K., et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002, 100:3175-3182.
190. Hiramatsu H., Nishikomori R., Heike T., Ito M., Kobayashi K., Katamura K., et al. Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model. Blood 2003, 102:873-880.
191. Ishikawa F., Yasukawa M., Lyons B., Yoshida S., Miyamoto T., Yoshimoto G., et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor (gamma) chain(null) mice. Blood 2005, 106:1565-1573.
192. King M., Pearson T., Shultz L.D., Leif J., Bottino R., Trucco M., et al. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin. Immunol. 2008, 126:303-314.
193. Brehm M.A., Cuthbert A., Yang C., Miller D.M., DiIorio P., Laning J., et al. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin. Immunol. 2010, 135:84-98.
194. Unger W.W., Pearson T., Abreu J.R., Laban S., van der Slik A.R., der Kracht S.M., et al. Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice. PLoS One 2012, 7:e49213.
195. Viehmann Milam A.A., Maher S.E., Gibson J.A., Lebastchi J., Wen L., Ruddle N.H., et al. A humanized mouse model of autoimmune insulitis. Diabetes 2014, 63:1712-1724.
196. Chatenoud L., Thervet E., Primo J., Bach J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:123-127.
197. Chatenoud L., Primo J., Bach J.F. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 1997, 158:2947-2954.
198. Chatenoud L. Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?. Nat. Rev. Endocrinol. 2010, 6:149-157.
199. Sherry N., Hagopian W., Ludvigsson J., Jain S.M., Wahlen J., Ferry R.J., et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011, 378:487-497.
200. Waldron-Lynch F., Henegariu O., Deng S., Preston-Hurlburt P., Tooley J., Flavell R., et al. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci. Transl. Med. 2012, 4. 118ra12.
201. Rongvaux A., Willinger T., Martinek J., Strowig T., Gearty S.V., Teichmann L.L., et al. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 2014, 32:364-372.
202. Wong A.S., Mortin-Toth S., Sung M., Canty A.J., Gulban O., Greaves D.R., et al. Polymorphism in the innate immune receptor SIRPα controls CD47 binding and autoimmunity in the nonobese diabetic mouse. J. Immunol. 2014, 193:4833-4844.
203. Steinman L., Shoenfeld Y. From defining antigens to new therapies in multiple sclerosis: honoring the contributions of Ruth Arnon and Michael Sela. J. Autoimmun. 2014, 54:1-7.
204. Gershwin M.E., Shoenfeld Y. Abul Abbas: an epitome of scholarship. J. Autoimmun. 2013, 45:1-6.